PDCD1 and neoplasm: Inhibition of CTLA-4 and PD-1 act on distinct pathways, e.g., central vs. peripheral immunity, the blockade of both pathways is complementary suggesting that simultaneous inhibition of these targets have additional anti-tumor activity (23).